NCT00394654已完成2 期
A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy of MEDI-528, a Humanized Anti-Interleukin-9 Monoclonal Antibody, on Late Asthmatic Response Induced By Allergen Inhalation In Adults With Atopic Asthma
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 3
- 主要终点
- Effect of MEDI-528 on Late Asthmatic Response (LAR) After Inhaled Allergen Challenge at Day 7
研究概览
简要总结
This is a Phase 2a, randomized multicenter study to evaluate the efficacy of MEDI-528 on LAR in adult patients with atopic asthma.
详细描述
This study (MI-CP138) is a Phase 2a, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy of MEDI-528 on LAR in adult patients with atopic asthma. Approximately three investigative sites in Canada will participate in this study, with up to 40 evaluable patients randomized in a 1:1 ratio to receive MEDI-528 (9.0 mg/kg) or placebo as a single IV infusion.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female adults, age 18 through 65 years of age at the time of screening;
- •Written informed consent obtained from the patient prior to receipt of any study medication or beginning study procedures;
- •Previously documented diagnosis of asthma of > 1 year duration, based on episodic symptoms of airflow obstruction, at least partial reversibility of airflow obstruction, with alternative diagnoses (e.g., chronic obstructive pulmonary disease) ruled out;
- •AHR in the methacholine challenge test with a PC20 (provoking concentration of methacholine to cause a 20% fall in FEV1) ≤ 16 mg/mL (Crapo, 2000);
- •Have dual response of EAR, defined as a decrease in FEV1 ≥ 20% at 0 to 3 hours after inhalation, and LAR, defined as a decrease in FEV1 ≥ 15% 3 to 7 hours after inhalation, to inhaled allergen;
- •Asthma symptoms are adequately controlled on short-acting β2 agonists (e.g., albuterol) alone;
- •Have had no significant changes in regular asthma medications and no acute asthma exacerbations requiring corticosteroid rescue, hospitalization, or emergency department visits for at least 4 weeks prior to screening and up through the time of the first dose of study drug on Study Day
- •Sexually active women, unless surgically sterile or at least 1 year post-menopausal, must have used an effective method of avoiding pregnancy (including oral or implanted contraceptives, intrauterine device, female condom, diaphragm with spermicide, cervical cap, abstinence, use of a condom by the sexual partner or sterile sexual partner) for 21 days prior to the first dose of study drug on Study Day 0, and must agree to continue using such precautions through Study Day
- •Cessation of birth control after this point should be discussed with a responsible physician. Sexually active men, unless surgically sterile, must likewise use an effective method of birth control (condom) and must agree to continue using such precautions through Study Day 126;
- •Able to complete the follow-up period through Study Day 126, as required by the protocol.
- •Willing to forego other forms of experimental treatment and study procedures during the study; and
- •Able to provide spirometric readings that meet American Thoracic Society (ATS) standards (ATS, 1995).
排除标准
- •Receipt of MEDI-528 in any previous clinical study;
- •History of allergy or adverse reactions to any component of the MEDI-528 formulation;
- •Lung disease other than allergic asthma (e.g. chronic bronchitis);
- •Current use of any systemic or inhaled immunosuppressive drugs, including systemic and inhaled corticosteroids (topical corticosteroids are permitted), long-acting β2 agonists, leukotriene antagonists, cromolyn sodium, nedocromil sodium, theophylline or any inhaled or systemic medication for asthma other than short-acting β2 agonists, for at least 4 weeks prior to study drug administration on Study Day
- •Current use of any β-adrenergic antagonist (e.g. propranolol).
- •Any disease or illness, other than asthma, that may require the use of systemic corticosteroids during the study period.
- •Acute illnesses or evidence of clinically significant active infection, such as fever ³ 38.0°C (100.5°F) at screening and through the time of the study drug administration on Study Day 0;
- •Current allergy-vaccination therapy (i.e., desensitization immunotherapy) with less than 3 months of stable maintenance doses prior to the baseline allergen inhalation challenge;
- •Receipt of any investigational drug therapy within 30 days or any biologic(s) within 5 half-lives of the agent prior to the first dose of study drug through Study Day 150;
- •Receipt of any therapy with a leukocyte-depleting agent unless recovery in white cell count has been documented before screening;
- •Pregnancy (sexually active females must have a negative serum pregnancy test at screening and a negative urine pregnancy test prior to study drug administration on Study Day 0);
- •Is a nursing mother at the time of study enrollment;
- •Evidence of infection with hepatitis B or C virus, or HIV-1 or HIV-2, or active infection with hepatitis A;
- •History of significant systemic disease (e.g., cancer; infection; coronary artery disease or other cardiovascular disease; or hematological, renal, hepatic, endocrinologic, neurologic, rheumatologic, or gastrointestinal disease);
- •History of cancer other than nonmelanoma skin cancer or cervical carcinoma-in-situ that have been treated successfully with curative therapy;
- •History of primary immunodeficiency;
- •History of pancreatitis;
- •History of use of tobacco products within 2 years of baseline or history of smoking >= 10 pack-years;
- •Elective surgery planned from the time of screening through Study Day 126;
- •Clinically significant abnormalities (other than asthma) upon physical examination prior to study drug administration on Study Day 0;
- •Clinically significant abnormality, as determined by the investigator, on 12-lead ECG or chest radiograph at the time of screening;
- •At the time of screening, any of the following abnormalities: aspartate transaminase (AST), alanine transaminase (ALT), or amylase > 1.5 × above the upper limits of normal (ULN); or serum creatinine > 1.3 × ULN; or any other abnormal laboratory values in the screening panel that, in the opinion of the principal investigator (PI), are judged to be clinically significant; or
- •Evidence of any systemic disease or respiratory disease (other than asthma), any finding upon physical examination or history of any disease that, in the opinion of the PI or medical monitor, may compromise the safety of the patient in the study or confound the analysis of the study.
研究组 & 干预措施
MEDI528 9 mg/kg
Experimental
MEDI-528 at a single dose of 9 mg/kg administered as an intravenous infusion
干预措施: MEDI-528 9 mg/kg (Biological)
PLACEBO
Placebo Comparator
Placebo administered as a single intravenous infusion
干预措施: Placebo (Other)
结局指标
主要结局
Effect of MEDI-528 on Late Asthmatic Response (LAR) After Inhaled Allergen Challenge at Day 7
时间窗: Day 7
Change from baseline (percent reduction) in mean maximum decline of forced expiratory volume in one second (FEV1) during LAR at 3 to 7 hours after an inhaled allergen challenge.
Effect of MEDI-528 on LAR After Inhaled Allergen Challenge at Day 28
时间窗: Day 28
Change from baseline (percent reduction) in mean maximum decline of FEV1 during LAR at 3 to 7 hours after an inhaled allergen challenge.
Effect of MEDI-528 on LAR After Inhaled Allergen Challenge at Day 56
时间窗: Day 56
Change from baseline (percent reduction) in mean maximum decline of FEV1 during LAR at 3 to 7 hours after an inhaled allergen challenge.
Effect of MEDI-528 on LAR After Inhaled Allergen Challenge at Day 7
时间窗: Day 7
Change from baseline (percent reduction) in mean maximum decline of area under the concentration-time curve (AUC) of the participants FEV1 during LAR at 3 to 7 hours after an inhaled allergen challenge.
次要结局
- Area Under the Concentration Curve From Time Zero to Last Measurable Concentration [AUC(0-t)](Days -6 to -1, 8, 29, and 57)
- Area Under the Concentration Curve From Time Zero to Infinity [AUC(0-infinity)](Days -6 to -1, 8, 29, and 57)
- Observed Maximum Nasal Lavage Concentration (Cmax)(Days -6 to -1, 8, 29, and 57)
- Incidence of Adverse Events(Days 0 - 126)
- Incidence of Serious Adverse Events(Days 0 - 126)
- Incidence of Anti-drug Antibodies (ADA) to MEDI-528(Days 0, 27, 55, 84, and 126)
- Time to Observed Maximum Serum Concentration (Tmax)(Days 0, 6, 7, 27, 55, 84, and 126)
- Time to Observed Maximum Sputum Concentration (Tmax)(Days -21 to -7, 7, 28, and 56)
- Time to Observed Maximum Nasal Lavage Concentration (Tmax)(Days -6 to -1, 8, 29, and 57)
- Observed Maximum Serum Concentration (Cmax)(Days 0, 6, 7, 27, 55, 84, and 126)
- Observed Maximum Sputum Concentration (Cmax)(Days -21 to -7, 7, 28, and 56)
- Percent of Total Area Under the Concentration Curve Extrapolated From Last Measurable Time to Infinity [AUC(Ext)](Days -6 to -1, 8, 29, and 57)
- Terminal Phase Half-Life (T1/2)(Days -6 to -1, 8, 29, and 57)
- Total Body Clearance (CL)(Days 0, 6, 7, 27, 55, 84, and 126)
- Terminal Phase Volume of Distribution (Vz)(Days 0, 6, 7, 27, 55, 84, and 126)
- Area Under the Concentration Curve From Time Zero to Last Measurable Concentration [AUC(0-t)](Days 0, 6, 7, 27, 55, 84, and 126)
- Area Under the Concentration Curve From Time Zero to Last Measurable Concentration [AUC(0-t)](Days -21 to -7, 7, 28, and 56)
- Area Under the Concentration Curve From Time Zero to Infinity [AUC(0-infinity)](Days 0, 6, 7, 27, 55, 84, and 126)
- Area Under the Concentration Curve From Time Zero to Infinity [AUC(0-infinity)](Days -21 to -7, 7, 28, and 56)
- Percent of Total Area Under the Concentration Curve Extrapolated From Last Measurable Time to Infinity [AUC(Ext)](Days 0, 6, 7, 27, 55, 84, and 126)
- Percent of Total Area Under the Concentration Curve Extrapolated From Last Measurable Time to Infinity [AUC(Ext)](Days -21 to -7, 7, 28, and 56)
- Terminal Phase Half-Life (T1/2)(Days 0, 6, 7, 27, 55, 84, and 126)
- Terminal Phase Half-Life (T1/2)(Days -21 to -7, 7, 28, and 56)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
2 期
GB001 in Adult Participants With Chronic RhinosinusitisChronic Rhinosinusitis With Nasal Polyps (CRSwNP)Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)NCT03956862GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.97
已完成
2 期
Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder CancerUrothelial CarcinomaBladder CancerNCT02500121Matthew Galsky108
招募中
2 期
A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).Intestinal Failure Associated Liver DiseaseNCT05919680NorthSea Therapeutics B.V.36
已完成
2 期
Nitric Oxide Releasing Solution (NORS) For The Treatment Of Human Papillomavirus(HPV) Verrucae Plantaris (Plantar Warts)Verruca PlantarisNCT05877313Sanotize Research and Development corp.20
已完成
2 期
Clinical Study to Investigate the Efficacy of Orally Administered SA001 in Patients With Primary Sjögren's SyndromePrimary Sjögren's Syndrome (pSS)NCT05269810Samjin Pharmaceutical Co., Ltd.28